StockNews.AI
ECOR
StockNews.AI
3 hrs

electroCore's Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards

1. Truvaga™ Plus named 'Best Relaxation Gadget' in Esquire’s 2025 Sleep Awards. 2. Recognition highlights Truvaga Plus's effectiveness in anxiety reduction and sleep improvement. 3. ElectroCore aims to enhance wellness through bioelectronic devices like Truvaga Plus. 4. Truvaga Plus offers a drug-free method for relaxation in just two minutes. 5. Unique market position as a leading consumer wellness device using vagus nerve stimulation.

6m saved
Insight
Article

FAQ

Why Bullish?

The recognition from Esquire will likely increase consumer interest and sales, similar to past award winners in the wellness gadget category that experienced stock price boosts post-announcements.

How important is it?

The article showcases a significant product validation, enhancing brand reputation and likely translating to increased sales.

Why Short Term?

Immediate consumer interest may drive sales and investor attention, affecting stock price within the next quarter.

Related Companies

HIMSTHRYMDVL
ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its Truvaga™ Plus handheld vagus nerve stimulation (nVNS) device has been named the “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards. The annual Sleep Awards from Esquire recognize the most effective and innovative solutions for improving rest and recovery. Truvaga Plus was selected by the magazine’s editors after extensive hands-on testing, earning recognition for its ability to calm the nervous system, reduce stress, and promote restorative sleep in just two-minute sessions. “We are honored to be recognized in Esquire’s Sleep Awards,” said Kelly Benning, Senior Vice President of Truvaga at electroCore. “This recognition is a powerful validation for Truvaga Plus. Sleep is one of the most universal health challenges people face, and having an independent editorial team highlight our device builds confidence for consumers seeking a proven, drug-free way to relax, recharge, and sleep better.” About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com. About Truvaga Plus Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company’s proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease. Backed by 20+ years of research in bioelectronic medicineMade in the USA and Shipped from the USADrug-free and non-invasive technology for stress relief and sleepQuick two-minute sessions that fit easily into daily routines30-Day risk-free trial available at www.truvaga.com Truvaga Plus stands out as one of the few consumer wellness devices that leverages vagus nerve stimulation science, offering a natural alternative to medications and supplements for relaxation and sleep. For more information on Truvaga Plus, or to purchase directly, visit www.truvaga.com. Forward-Looking Statements This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated results from being Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards, the benefits of Truvaga Plus, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov. Contact: ECOR Investor Relations(973) 302-9253investors@electrocore.com ECOR Media Relations(973) 435-8354media-inquiries@electrocore.com

Related News